Oto vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
London digital CBT app for tinnitus with DEFINE Trial evidence showing 86% benefit in one month; £2.8M seed competing with Widex and ReSound for 750M global tinnitus sufferers needing accessible specialist care.
About
Oto is a London-based digital health company providing clinically validated, app-based CBT (cognitive behavioral therapy) treatment for tinnitus — the persistent ringing, buzzing, or hissing in the ears that affects 15% of the global population (750 million+ people) with no pharmaceutical cure — delivering structured therapeutic programs designed by tinnitus specialists that help patients manage and reduce tinnitus distress through evidence-based psychological and sound therapy techniques. Founded and backed with £2.8 million in seed funding raised in 2022, Oto demonstrated in the DEFINE Trial (the largest randomized controlled trial for any digital tinnitus program) that 86% of users experience measurable benefits within one month of the program.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.